MARKET

GHRS

GHRS

Gh Research Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.98
-0.28
-2.73%
Closed 16:00 06/30 EDT
OPEN
10.13
PREV CLOSE
10.26
HIGH
10.13
LOW
9.76
VOLUME
51.33K
TURNOVER
287.57K
52 WEEK HIGH
30.43
52 WEEK LOW
8.72
MARKET CAP
519.17M
P/E (TTM)
-24.5752
1D
5D
1M
3M
1Y
5Y
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.12% at $0.82
Benzinga · 3d ago
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71
Benzinga · 06/23 22:22
Psychedelic Stock Gainers And Losers From June 22, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50
Benzinga · 06/22 20:34
Revive Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.43% at $0.31
Benzinga · 06/21 21:43
--Roth Capital Starts GH Research at Buy With $66 Price Target
MT Newswires · 06/16 05:00
Psychedelic Stock Gainers And Losers From June 14, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44
Benzinga · 06/14 20:34
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:
Benzinga · 06/13 21:31
Psychedelic Stock Gainers And Losers From June 10, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 6.16% at $0.67
Benzinga · 06/10 20:46
More
No Data
Learn about the latest financial forecast of GHRS. Analyze the recent business situations of Gh Research Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GHRS stock price target is 46.00 with a high estimate of 66.00 and a low estimate of 31.00.
High66.00
Average46.00
Low31.00
Current 9.98
EPS
Actual
Estimate
-0.14-0.11-0.07-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 33
Institutional Holdings: 32.24M
% Owned: 61.98%
Shares Outstanding: 52.02M
TypeInstitutionsShares
Increased
9
2.31M
New
6
136.72K
Decreased
7
123.41K
Sold Out
3
127.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. It focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The Company is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

Webull offers kinds of GH Research PLC stock information, including NASDAQ:GHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GHRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GHRS stock methods without spending real money on the virtual paper trading platform.